相关实验视频
Updated: Jun 29, 2025

09:44
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
19.2K
里瓦罗克萨班对突然感觉神经听力损失的补充疗法的影响
Mehrdad Rogha1, Ehsan Moshtaghi2
1Department of Otorhinolaryngology, Head and Neck Surgery, Isfahan University of Medical Sciences, Isfahan, Iran.
Advanced biomedical research
|March 25, 2024
概括
这项研究研究了利瓦罗克萨班 (RXA) 对于突然的感觉神经听力损失 (SSNHL). 虽然RXA显示出改善听力恢复的趋势,但与单独使用标准皮质类固醇治疗相比,结果在统计上并不显著.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 突发感应神经听力损失 (SSNHL) 是一种与血液凝固有潜在联系的危急疾病.
- 抗凝剂正在探索SSNHL的治疗效果,但研究是有限的.
研究的目的:
- 评估抗凝剂里瓦罗克萨班 (RXA) 在治疗突然神经感官听力损失 (SSNHL) 的疗效.
主要方法:
- 这是一项双盲随机临床试验,涉及34名SSNHL患者.
- 患者接受皮质类固醇治疗 (CST) 加RXA或单独接受CST.
- 听力恢复的评估是使用美国耳鼻喉科 - 头部和部手术学会标准进行的.
主要成果:
- 里瓦洛克萨班组的听力恢复率 (58.8%) 比仅服用皮质类固醇组 (47.1%) 高,但这种差异在统计学上并不显著.
- RXA治疗增加了听力恢复的几率,尽管不是显著的 (OR:2.327,P=0.518).
- 延迟治疗,增加纯音调平均值 (PTA) 和与降低听力恢复几率 (P<0.05) 相关.
结论:
- 里瓦洛克萨班 (RXA) 与单独使用皮质类固醇治疗相比,没有显示出SSNHL听力恢复的统计学显著改善.
- 尽管RXA组的康复率更高,但整体治疗结果并没有显著差异.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424

